United States securities and exchange commission logo June 29, 2023 Samuel Kintz President and Chief Executive Officer Enliven Therapeutics, Inc. 6200 Lookout Road Boulder, CO 80301 Re: Enliven Therapeutics, Inc. Registration Statement on Form S-3 Filed June 23, 2023 File No. 333-272909 Dear Samuel Kintz: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Knapp, Esq.